Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Europe’s CHMP Clears Sofosbuvir, Dolutegravir And Dalamanid

This article was originally published in The Pink Sheet Daily

Executive Summary

As well as new therapies for hepatitis C, HIV/AIDS and tuberculosis, the EU's CHMP issued a positive opinion on new active substance status for Biogen Idec's oral MS therapy dimethyl fumurate after the panel’s latest meeting.

Advertisement

Related Content

SGLT-2 Inhibitor Dapagliflozin Gets Another Chance At FDA
ViiV Secures Its First New Drug Approval With Tivicay
AstraZeneca/BMS's Dapagliflozin Needs European Epidemiological Study, But Headed For Strong Label

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS075084

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel